Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients-Reference-Cited by-同舟云学术

Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients

Published:2022-04 Issue: Volume:60 Page:103729
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Bajwa Hamza Mahmood^ORCID,Novak Frederik,Nilsson Anna Christine,Nielsen Christian,Holm Dorte K.,Østergaard Kamilla,Witt Agnes Hauschultz,Byg Keld-Erik,Johansen Isik S.,Mittl Kristen,Rowles William,Zamvil Scott S.,Bove Riley,Sabatino Joseph J.,Sejbaek Tobias^ORCID

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference36 articles.

1. Abbott. SARS-CoV-2 IgG II quant for the use with alinity i. 2021 April 2021.

2. Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease;AbdelRazek;Mult. Scler. Relat. Disord,2022

3. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies;Achiron;Ther. Adv. Neurol. Disord.,2021

4. Humoral immune response after the third SARS-CoV-2 mRNA vaccination in CD20 depleted people with multiple sclerosis;Achtnichts;Vaccines (Basel),2021

5. Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies;Ali;Vaccine,2021

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients—a longitudinal cohort study;Frontiers in Immunology;2024-09-05

2. Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination;Vaccines;2024-08-19

3. Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination;Annals of Clinical and Translational Neurology;2024-05-07

4. Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination;2024-01-24

5. Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy;Frontiers in Immunology;2024-01-08